While cell cycle checkpoint kinases are well recognized as tumor suppressors across cancer types, and the efficacy of inhibitors of these proteins (primarily ATR and CHK1) in targeting cancer has been frequently investigated (50), we lack systematic understanding of the relative contributions of each of these kinases to cancer initiation and progression. This evidence concerns the gene CHEK1 and neoplasm.